According to DelveInsight, the Non Alcoholic Fatty Liver Disease Market in 7MM is expected to witness a major change in the study period 2019-2032

DelveInsight's "Non Alcoholic Fatty Liver Disease Market" report provides a thorough comprehension of the Non Alcoholic Fatty Liver Disease, historical and forecasted epidemiology, and the Non Alcoholic Fatty Liver Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Non Alcoholic Fatty Liver Disease market report also proffers an analysis of the current Non Alcoholic Fatty Liver Disease treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

The Non Alcoholic Fatty Liver Disease market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.

Key takeaways from the Non Alcoholic Fatty Liver Disease Market Report
• According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It's estimated that about 25% of adults in the U.S. have NAFLD. Of those with NAFLD, about 20% have NASH (5% of adults in the US). Most people with NAFLD have simply fatty liver.
• A study by Golabi et al. (2015), 3,271 NHANES-III participants and the prevalence rates from NAFLD were 40.3% and 39.2% among 60-74 and >74 years old. Among aged 60-74, the risks for 5-year and 10-year all-cause mortality were associated with presence of NAFLD for 5-year and 1.22.
• Non Alcoholic Fatty Liver Disease Market Companies included Altimmune Inc, Merck Sharp & Dohme LLC, DSM Nutritional Products Inc, Indiana University, Better Therapeutics, Arizona Liver Health, Terns Inc, Alnylam Pharmaceuticals, Genentech, Oramed Ltd, and several others.
• Non Alcoholic Fatty Liver Disease Market Therapies included ALT-801, Placebo, BT-NCBT-00X, TERN-201, ALN-HSD, Icosabutate, BFKB8488A, and several others.

Download Sample Report- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Alcoholic Fatty Liver Disease Overview
Nonalcoholic fatty liver disease (NAFLD) refers to a group of liver disorders that affect persons who use little to no alcohol. The fundamental feature of NAFLD, as the name suggests, is an excess of fat deposited in liver cells. Nonalcoholic fatty liver disease is becoming more frequent over the world, particularly in Western countries. It is the most common type of chronic liver disease in the United States, affecting almost one-quarter of the population.

Nonalcoholic fatty liver disease Epidemiology Insights
Nonalcoholic fatty liver disease develops in four main stages. 1) Simple fatty liver (steatosis) (NAFL)-a largely harmless build-up of fat in the liver cells that may only be diagnosed during tests carried out for another reason, 2) non-alcoholic steatohepatitis (NASH) - a more serious form of NAFLD, where the liver has become inflamed, 3) fibrosis-where persistent inflammation causes scar tissue around the liver and nearby blood vessels, but the liver is still able to function normally, and 4) cirrhosis - the most severe stage, occurring after years of inflammation.

Nonalcoholic fatty liver disease Epidemiology Segmentation in the 7MM
• Total Nonalcoholic fatty liver disease Prevalent Cases
• Nonalcoholic fatty liver disease Age-specific Prevalent Cases
• Nonalcoholic fatty liver disease Stage-specific Prevalent Cases
• Nonalcoholic fatty liver disease Gender-specific Prevalent Cases
• Nonalcoholic fatty liver disease Diagnosed and Treatable Cases

Nonalcoholic fatty liver disease Market
Nonalcoholic fatty liver disease is part of the metabolic syndrome characterized by diabetes, or pre-diabetes (insulin resistance), being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. Not all patients have all the manifestations of the metabolic syndrome. Less is known about what causes NASH to develop. Researchers are focusing on several factors that may contribute to the development of NASH. These include oxidative stress (imbalance between pro-oxidant and anti-oxidant chemicals that lead to liver cell damage); production and release of toxic inflammatory proteins (cytokines) by the patient's own inflammatory cells, liver cells, or fat cells; liver cell necrosis or death, called apoptosis; adipose tissue (fat tissue) inflammation and infiltration by white blood cells; and gut microbiota (intestinal bacteria) which may play a role in liver inflammation.

Nonalcoholic fatty liver disease Market Insights
About 2 to 5 percent of adult Americans and up to 20 percent of those who are obese may suffer from the more severe condition NASH. The number of children who have NASH is not known. The presence of type 2 diabetes and other conditions associated with insulin resistance, such as polycystic ovarian syndrome are known risk factors for the development of fatty liver and NASH.

Scope of the Non Alcoholic Fatty Liver Disease Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 11 Years
• Non Alcoholic Fatty Liver Disease Market Companies included Altimmune Inc, Merck Sharp & Dohme LLC, DSM Nutritional Products Inc, Indiana University, Better Therapeutics, Arizona Liver Health, Terns Inc, Alnylam Pharmaceuticals, Genentech, Oramed Ltd, and several others.
• Non Alcoholic Fatty Liver Disease Market Therapies included ALT-801, Placebo, BT-NCBT-00X, TERN-201, ALN-HSD, Icosabutate, BFKB8488A, and several others.
• Market Drivers and Barriers
• KOL Views

Request Sample Report- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Non Alcoholic Fatty Liver Disease Executive Summary
3. Competitive Intelligence Analysis for Non-Alcoholic Fatty Liver Disease
4. Non Alcoholic Fatty Liver Disease Market Overview at a Glance
5. Non Alcoholic Fatty Liver Disease Disease Background and Overview
6. Patient Journey
7. Non Alcoholic Fatty Liver Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Non Alcoholic Fatty Liver Disease Unmet Needs
10. Key Endpoints of Non Alcoholic Fatty Liver Disease Treatment
11. Non Alcoholic Fatty Liver Disease Marketed Products
12. Non Alcoholic Fatty Liver Disease Emerging Therapies
13. Non Alcoholic Fatty Liver Disease Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Non Alcoholic Fatty Liver Disease Market Outlook
16. Access and Reimbursement Overview of Non Alcoholic Fatty Liver Disease
17. KOL Views
18. Non Alcoholic Fatty Liver Disease Market Drivers
19. Non Alcoholic Fatty Liver Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Do you have any query related to the report? Just speak to analyst- https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.